Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
ID: 335885Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/335885

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-329.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" aimed at supporting research on the long-term adverse effects of cancer therapies. This initiative seeks collaborative projects that investigate the mechanisms behind therapy-induced sequelae, aiming to clinically characterize these effects and develop interventions to prevent or mitigate them. The program emphasizes a multidisciplinary approach and encourages innovative methodologies, with eligible applicants including various educational institutions and organizations, particularly those serving underrepresented communities. Interested parties should note that the application deadline is November 5, 2024, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-21-329-Full-Announcement.html
    PAR-21-329.html
    The funding opportunity from the National Institutes of Health (NIH) aims to support research addressing adverse effects from cancer therapies that can lead to long-term health issues. The initiative focuses on collaborative projects investigating the mechanisms of treatment-induced sequelae to identify their clinical characteristics and develop interventions for prevention and management. Applications can include basic, translational, or clinical studies that either propose clinical trials or not. The announcement specifies eligible applicants and emphasizes a multidisciplinary approach to research. Key research areas include evaluating clinical markers for toxicity, conducting early-phase trials for mitigating strategies, and understanding the progression of acute to chronic adverse effects. The program encourages applicants to utilize innovative methodologies and develop robust data management plans. The maximum project duration is five years, with flexible budget limits based on actual needs. The deadline for applications adheres to standard NIH submission protocols, reinforcing the NIH's commitment to advancing knowledge and improving the quality of life for cancer survivors facing treatment-related challenges.
    Similar Opportunities
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers" through the R01 Clinical Trial Optional grant mechanism. This initiative aims to support multi-level intervention studies that address both individual and systemic barriers faced by survivors transitioning from pediatric to adult healthcare, with a focus on developing effective strategies for high-quality transitional care. A total funding amount of $10 million is available for fiscal years 2025 and 2026, with up to 12 awards anticipated, and applications are due by October 12, 2024. Interested applicants can find more information and guidelines in the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-027.html, and inquiries can be directed to grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at advancing cancer treatment through innovative nanotechnology-based diagnostics and therapeutics. This initiative supports advanced pre-clinical research focused on developing nanoparticle and nano-device interventions that enhance the effectiveness of cancer treatments, particularly in combination therapy, immunotherapy, and imaging. The program emphasizes multidisciplinary collaboration and requires proposals to outline clear milestones for project advancement, with a maximum budget of $475,000 in direct costs annually over a project period of up to four years. Interested applicants must submit their proposals by November 17, 2024, and can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.